Healthcare • Biotechnology
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if ALEC is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
30 top institutions tracked
Last 13F trend: accumulating (heavy)
Unlock crowding heatmapUnlock filer discoverySentiment: bearish
Last trade: sell 41 days ago
Red flags: 0
141 filers reported a long position in ALEC for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| TCG Crossover Management, LLC | $20.1M | 10M | Unchanged |
| BlackRock, Inc. | $15.8M | 7.8M | +1.4% |
| ACADIAN ASSET MANAGEMENT LLC | $8.9M | 4.4M | +9.3% |
| Nantahala Capital Management, LLC | $8.7M | 4.3M | +53.3% |
| VANGUARD CAPITAL MANAGEMENT LLC | $8.1M | 4M | +9% |
| Kynam Capital Management, LP | $7.7M | 3.8M | +90.4% |
| Merck & Co., Inc. | $7.1M | 3.5M | Unchanged |
| BALYASNY ASSET MANAGEMENT L.P. | $6.5M | 3.2M | +10.6% |
| 683 Capital Management, LLC | $6.4M | 3.2M | Unchanged |
| D. E. Shaw & Co., Inc. | $5.9M | 3M | -11.2% |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.